Krystal Sees Success With Topical Gene Therapy In Debilitating Rare Skin Disorder

 
• By Jessica Merrill

A regulatory filing for Vyjuvek in the US is targeted for the first half of 2022 following the positive results of a Phase III trial, positioning Krystal for its first commercial launch.

Business success concept with target as motivation (3D Rendering)
Krystal reported positive Phase III data for a topical gene therapy • Source: Shutterstock

More from Gene Therapies

More from Advanced Therapies